Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data ReleasesSeeking Alpha • 06/20/25
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 CongressGlobeNewsWire • 06/13/25
Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/05/25
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 06/03/25
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 05/29/25
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 CongressGlobeNewsWire • 05/14/25
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/13/25
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 05/12/25
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/06/25
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/06/25
Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient CongressGlobeNewsWire • 04/05/25
Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hardInvezz • 03/31/25
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA ClearanceZacks Investment Research • 03/28/25
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug AdministrationGlobeNewsWire • 03/27/25
Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene TherapySeeking Alpha • 03/21/25
BEAM Down Despite Positive Initial Data From Genetic Disorder StudyZacks Investment Research • 03/11/25
Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via EquityBenzinga • 03/10/25
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing MutationGlobeNewsWire • 03/10/25